Brexpiprazole
Back to searchMolecule Structure
Scientific Name
Brexpiprazole
Description of the Drug
Brexpiprazole is a serotonin–dopamine activity modulator used in the treatment of major depressive disorder as an adjunct and schizophrenia.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09128
http://www.drugbank.ca/drugs/DB09128
Brand Name(s)
Rexulti
Company Owner(s)
Otsuka Pharmaceutical Co Ltd, Teva Pharmaceuticals Usa Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Dopamine D2 receptor | SINGLE PROTEIN | PARTIAL AGONIST | CHEMBL217 |
Serotonin 1a (5-HT1a) receptor | SINGLE PROTEIN | PARTIAL AGONIST | CHEMBL214 |
Serotonin 2a (5-HT2a) receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL224 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL1037592 | |
PharmGKB | PA166160053 | |
Human Metabolome Database | HMDB0249379 | |
DrugBank | DB09128 | |
PubChem: Thomson Pharma | 17430973 | |
PubChem | 11978813 | |
LINCS | LSM-45790 | |
Nikkaji | J3.002.326I | |
BindingDB | 194780 | |
EPA CompTox Dashboard | DTXSID40238527 | |
DrugCentral | 5014 | |
ChemicalBook | CB52681994 | |
Guide to Pharmacology | 7672 | |
rxnorm | BREXPIPRAZOLE | REXULTI |
ChEBI | 134716 | |
ZINC | ZINC000084758479 |